DBS System mentioned in the press release of “La Côte” of March 19th
Link to Article Source: http://goo.gl/66W6kh
Link to Article Source: http://goo.gl/66W6kh
The partners of the ENTENTE-project together with the European Commission and EuropaBio (the European association for BioIndustries) are proud to announce the companies selected to present at the ENTENTE Life Sciences Investment Forum, taking place on October 9th at the Stanhope Hotel in Brussels, during the 2014 European Biotech Week.
Selected companies
The 28 European selected companies have been evaluated by the selection committee members among a pool of 100 innovative companies active in the Life Sciences sector and seeking investment opportunities and international exposure. The entrepreneurs will pitch their innovation, developments and needs in front of an international jury consisting of about 40 business angels, venture capitalists, corporate investors and other industry experts.
Link to Source Article: http://goo.gl/ygHtRD
HemaXis DB is a FDA Class 1 medical device. HemaXis DX is in development and for research purposes only. Use of HemaXis devices in Laboratory Developed Tests (LDTs) requires further processing including the establishment of performance characteristics and successful validation by the laboratory in a manner consistent with local regulatory requirements.
By using this website you are agreeing to our Terms and Conditions.
DBS System SA
Rte des Avouillons 6
CH-1196 Gland
Switzerland
Tel: +41 (0) 78 624 70 15
Email: info@dbs-system.ch
Read Our Privacy Policy
Read Our General Terms and Conditions of Sale
Read Our Shipping Information